Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)

被引:34
|
作者
Griffiths, Robert [1 ,2 ]
Gleeson, Michelle [1 ]
Knopf, Kevin [3 ]
Danese, Mark [1 ]
机构
[1] Outcomes Insights Inc, Westlake Village, CA USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Calif Pacific Med Ctr, San Francisco, CA USA
关键词
CHEMOTHERAPY PLUS RITUXIMAB; ELDERLY-PATIENTS; COMORBIDITY INDEX; CHOP;
D O I
10.1186/1471-2407-10-625
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Diffuse large B-cell lymphoma (DLBCL) comprises 31% of lymphomas in the United States. Although it is an aggressive type of lymphoma, 40% to 50% of patients are cured with treatment. The study objectives were to identify patient factors associated with treatment and survival in DLBCL. Methods: Using Surveillance, Epidemiology, and End Results (SEER) registry data linked to Medicare claims, we identified 7,048 patients diagnosed with DLBCL between January 1, 2001 and December 31, 2005. Patients were followed from diagnosis until the end of their claims history (maximum December 31, 2007) or death. Medicare claims were used to characterize the first infused chemo-immunotherapy (C-I therapy) regimen and to identify radiation. Multivariate analyses were performed to identify patient demographic, socioeconomic, and clinical factors associated with treatment and with survival. Outcomes variables in the survival analysis were all-cause mortality, non-Hodgkin's lymphoma (NHL) mortality, and other/unknown cause mortality. Results: Overall, 84% (n = 5,887) received C-I therapy or radiation treatment during the observation period: both, 26%; C-I therapy alone, 53%; and radiation alone, 5%. Median age at diagnosis was 77 years, 54% were female, 88% were white, and 43% had Stage III or IV disease at diagnosis. The median time to first treatment was 42 days, and 92% of these patients had received their first treatment by day 180 following diagnosis. In multivariate analysis, the treatment rate was significantly lower among patients >= 80 years old, blacks versus whites, those living in a census tract with >= 12% poverty, and extra-nodal disease. Blacks had a lower treatment rate overall (Hazard Ratio [HR] 0.77; P < 0.001), and were less likely to receive treatment within 180 days of diagnosis (Odds Ratio [OR] 0.63; P = 0.002) than whites. In multivariate survival analysis, black race was associated with higher all-cause mortality (HR 1.24; P = 0.01) and other/unknown cause mortality (HR 1.35; P = 0.01), but not mortality due to NHL (HR 1.16; P = 0.19). Conclusions: In elderly patients diagnosed with DLBCL, there are large differences in treatment access and survival between blacks and whites.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population
    Blansky, Deanna
    Fazzari, Melissa
    Mantzaris, Ioannis
    Rohan, Thomas
    Hosgood, H. Dean
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 581 - 589
  • [22] Mutational Landscape of Diffuse Large B-Cell Lymphoma (DLBCL) in Mexican Patients
    Candelaria, Myrna
    Gutierrez-Hernandez, Olga
    Diaz-Chavez, Jose
    Cerrato, Dennis
    Gutierrez-Ramirez, Francisco J.
    Aviles, Alejandro
    BLOOD, 2023, 142
  • [23] Diffuse large B-cell lymphoma in the older
    Gutierrez, A.
    Mestre, F.
    Perez-Manga, G.
    Rodriguez, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 (01) : 59 - 72
  • [24] Conditional survival of patients with diffuse large B-cell lymphoma
    Moller, MB
    Pedersen, NT
    Christensen, BE
    CANCER, 2006, 106 (10) : 2165 - 2170
  • [25] Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults
    Guadamuz, Jenny S.
    Ozenberger, Katharine
    Qato, Dima M.
    Ko, Naomi Y.
    Saffore, Christopher D.
    Adimadhyam, Sruthi
    Cha, Ashley S.
    Moran, Kellyn M.
    Sweiss, Karen
    Patel, Pritesh R.
    Chiu, Brian C. -H.
    Calip, Gregory S.
    MEDICINE, 2019, 98 (46) : e17960
  • [26] The Role of HIV in Race-Based Differences in Diffuse Large B-Cell Lymphoma(DLBCL) Treatment and Outcomes
    Blue, Brandon
    Sanfilippo, Kristen M.
    Riedell, Peter A.
    Lynch, Ryan
    Luo, Suhong
    Carson, Kenneth R.
    BLOOD, 2016, 128 (22)
  • [27] Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older
    Toomey, Christina E.
    Muzikanksy, Alona
    Lee, Alfred Ian
    Barnes, Jeffrey A.
    Michaelson, James S.
    Abramson, Jeremy S.
    Hochberg, Ephraim P.
    BLOOD, 2010, 116 (21) : 323 - 324
  • [28] Risk Factors for Early Death after Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Mantripragada, Kalyan
    Castillo, Jorge J.
    Olszewski, Adam J.
    BLOOD, 2015, 126 (23)
  • [29] Treatment for older diffuse large B-cell lymphoma patients with cognitive impairment and dementia
    Saffore, Christopher D.
    Ko, Naomi Y.
    Holmes, Holly M.
    Patel, Pritesh R.
    Sweiss, Karen
    Adimadhyam, Sruthi
    Chiu, Brian C. H.
    Calip, Gregory S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 356 - 357
  • [30] Characteristics and Outcome of critically ill Patients with diffuse large B-Cell Lymphoma (DLBCL)
    Wohlfarth, P.
    Carlstroem, A.
    Staudinger, T.
    Clauss, S.
    Skrabs, K.
    Porpaczy, E.
    Schiefer, A. I.
    Valent, P.
    Jaeger, U.
    Sperr, W. R.
    Schellongowski, P.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2015, 110 (04) : 297 - 297